PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-58.56%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-71.47%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-119.12%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-119.12%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-133.89%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-134.37%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-134.90%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
-0.28%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-0.55%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
-1.06%
Dividend reduction while AR stands at 0.00%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
215.67%
OCF growth above 1.5x AR's 7.56%. David Dodd would confirm a clear edge in underlying cash generation.
81.87%
FCF growth above 1.5x AR's 15.38%. David Dodd would verify if the firm’s strategic investments yield superior returns.
4.05%
10Y revenue/share CAGR under 50% of AR's 226.56%. Michael Burry would suspect a lasting competitive disadvantage.
-51.60%
Negative 5Y CAGR while AR stands at 76.73%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-71.32%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
144.96%
10Y OCF/share CAGR above 1.5x AR's 83.73%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
20.20%
Below 50% of AR's 266.41%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
-54.81%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-309.87%
Negative 10Y net income/share CAGR while AR is at 196.15%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-171.02%
Negative 5Y net income/share CAGR while AR is 129.17%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-138.27%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
145.45%
10Y equity/share CAGR above 1.5x AR's 24.95%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
46.21%
5Y equity/share CAGR above 1.5x AR's 2.75%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
-0.10%
Negative 3Y equity/share growth while AR is at 31.02%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
396.94%
10Y dividend/share CAGR above 1.5x AR's 12.12%. David Dodd checks if the firm's robust cash flows justify outpacing the competitor's increases.
162.38%
Dividend/share CAGR of 162.38% while AR is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
6.81%
3Y dividend/share CAGR of 6.81% while AR is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
12.34%
Our AR growth while AR is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
-80.00%
Inventory is declining while AR stands at 0.00%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-3.69%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-5.39%
We have a declining book value while AR shows 1.35%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-0.65%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
No Data
No Data available this quarter, please select a different quarter.
30.49%
SG&A growth well above AR's 24.05%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.